CVC Capital Partners Shares Surge 3.3% on Recordati Pharma Bid
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
private-equitymergers-acquisitions
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Shares in CVC Capital Partners surged 3.3% on 22 May 2026 following the formal launch of its tender offer for Italian pharmaceutical company Recordati. The offer, valued at 2.4 billion euros, is priced at 48.50 euros per share. The mandatory takeover bid was triggered after CVC’s acquisition of a 30% stake from the company's founding family. The move is a significant entry into the healthcare sector for the Amsterdam-listed private equity firm. It represents one of the largest European cross-border healthcare deals of the year.
The acquisition represents a strategic shift into defensive assets by a major financial sponsor. CVC Capital Partners, historically focused on consumer and business services, is diversifying its portfolio with a stable, cash-generative pharmaceutical business. The deal arrives during a period of significant capital deployment by private equity firms in Europe. Firms are sitting on record levels of dry powder, estimated at over 2.5 trillion USD globally, seeking resilient targets amid macroeconomic uncertainty.
Healthcare has seen heightened M&A activity in 2026, with deals like GSK's 1.5 billion USD acquisition of a respiratory portfolio in January. The current backdrop features moderate but sticky core inflation in the Eurozone and a European Central Bank policy rate at 3.25%. Recordati was strategically vulnerable following a generational transition within the founding family, creating an opportunity for a buyer to secure a controlling stake.
CVC's stock closed the session at 17.85 euros, adding over 500 million euros to its market capitalization, which now stands above 18 billion euros. The 3.3% single-day gain significantly outperformed the Euro Stoxx 50 index, which was flat for the session. The tender offer price of 48.50 euros for Recordati represents a 32% premium to the stock's average price in the 30 days preceding the initial stake announcement. Recordati's shares traded at 47.90 euros at the close.
| Metric | CVC (22 May) | Peer Average (KKR, EQT, Blackstone) |
|---|---|---|
| YTD Performance | +11.4% | +8.1% |
| P/E Ratio | 14.2x | 15.8x |
The offer implies an enterprise value to EBITDA multiple of approximately 12.5x for Recordati, in line with recent European mid-cap pharma transactions. CVC's bid is fully funded by equity from its latest 26 billion euro fund, CVC Capital Partners IX. The bid acceptance period runs for four weeks, ending on 19 June 2026.
The transaction will likely increase investor focus on other mid-cap European pharmaceutical firms perceived as acquisition targets. Companies like Laboratorios Farmaceuticos Rovi SA and Almirall SA may see positive price momentum, potentially in the 2-5% range, as deal speculation increases. Conversely, competing private equity bidders that lost out, such as Advent International, may redirect capital to similar assets, tightening valuations in the sector.
A key risk is regulatory scrutiny from the Italian government, which has recently expanded its 'golden power' legislation to cover the pharmaceutical sector. This could delay or impose conditions on the deal's closure, capping near-term upside for both stocks. Trading flow data indicates short-term momentum funds are building long positions in CVC, while arbitrage desks are simultaneously buying Recordati and shorting CVC to capture the deal spread.
The primary catalyst is the tender offer results, due by 20 June 2026. Acceptance above 90% of Recordati shares would allow CVC to execute a swift squeeze-out and delisting. A key level to monitor is CVC's 50-day moving average at 17.20 euros, which now acts as near-term support. The next major test for the combined thesis will be CVC's Q2 earnings report scheduled for 31 July 2026, which may provide an update on integration plans.
Investors should also watch the Italian Competition Authority's review, expected by mid-July. Any indication of required divestments would be a material development. On a sector level, the success of this deal may catalyze a fresh wave of healthcare M&A, making the STOXX Europe 600 Health Care index a performance benchmark to track.
CVC has historically maintained a dividend payout ratio of 60-80% of its distributable earnings. The acquisition is not expected to jeopardize this policy in the near term, as the deal is funded by dedicated fund capital, not corporate debt. However, medium-term dividend growth may be subdued as management prioritizes integrating Recordati's cash flows. Analysts project the deal could be accretive to CVC's earnings per share by 2027.
The 2.4 billion euro valuation is smaller than the landmark 2025 acquisition of Biotest by a Bain Capital consortium for 4.8 billion euros but larger than most platform-building deals in the sector. The multiple paid is consistent with the premium for high-quality, family-owned assets with strong regional branding, as seen in the 2021 buyout of German pharma firm Stada by Bain and Cinven.
Private equity holding periods for European pharma assets have averaged 5-7 years over the past decade. Typical exit routes include strategic sales to larger pharmaceutical companies or secondary buyouts. Notable examples include the 2020 sale of Nordic pharma company Orifarm to Advent International, which was later sold to a Chinese consortium in 2024, generating an internal rate of return of over 25% for the sponsor.
CVC's pivot into healthcare validates the sector's defensive appeal and signals aggressive capital deployment from major financial sponsors.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.